All News
ICYMI: Towards Personalised Care in Rheumatoid Arthritis
Since the millennium, we have seen an expansion in the number of advanced treatments both biologic and targeted synthetic disease modifying anti-rheumatic drugs for rheumatoid arthritis. The challenge remains on how best to characterise the subtypes of RA in order to choose the best drug to ensure optimal outcome for patients.
Read Article
Post-Menopausal Osteoporosis Review and Recommendations
A recent New England Journal review of post-menopausal osteoporosis (OP) provided updated information, strategies and a review of guidelines and clinical recommendations. Here are the salient highlights.
Read Article
ICYMI: The Heart of Lupus
Few people are aware of the EULAR recommendations for cardiovascular risk management in SLE published in 2022. The recommendations had 4 overarching principles: increase awareness of elevated cardiovascular risk, need for regular cardiovascular screening, assess and manage modifiable risk factors, and patient education. During ACR 2023 Convergence, several abstracts were presented evaluating the prevalence of CV disease and exploring new tools to predict CV disease.
Read Article
Calcineurin Inhibitors in Lupus Nephritis
Dr. Kathryn Dao discusses abstract 1509 with Dr. Gabriel Figueroa-Parra at the 2023 ACR Convergence meeting in San Diego, CA.
https://t.co/4CjJ8Ri3ym https://t.co/KUONVdMfBB
Dr. John Cush RheumNow ( View Tweet)
How do we Diversify Clinical Trials?
Dr. Rachel Tate talks with Dr. Irene Blanco at the 2023 ACR Convergence meeting in San Diego, CA.
https://t.co/fZ7kKfdRwP https://t.co/Non3X7zOxA
Dr. John Cush RheumNow ( View Tweet)
Is MTX Safe in the Elderly?
Dr.Cush reviews this past week's news from RheumNow. Good news is that nearly 99% of adult rheumatology positions matched! But 45% of pediatric fellowship programs and 39% of pediatric rheum slots were unfilled.
https://t.co/un9CbyYooL https://t.co/ilABvgr7bH
Dr. John Cush RheumNow ( View Tweet)
Pneumocystis Jiroveci Pneumonia (PJP) Risk
https://t.co/6kP3IjmHi1 https://t.co/ERwIeTKBYp
Dr. John Cush RheumNow ( View Tweet)
resolved HBV (HBsAg-, HBcAb+, HBsAb+) are at low risk of reactivation (~2%) w/ TNFi or biologics. But in a high risk endemic region (ie, Korea) this risk is higher. Study of 416 such pts HBV reactivation rate 3.5% @5 yrs, 6.1% @10 yrs & 24.2% @17 yrs https://t.co/oQ5e6O9wds https://t.co/50vBtapJVN
Dr. John Cush RheumNow ( View Tweet)
Risk of Hepatitis B reactivation is assessed by serology
- Resolved HBV (low risk reactiv): HBsAg-neg, HBcAb–pos & Pos HBsAb
- If HBcAb(+), HBsAb negativity incr risk;
- HBsAg(-), HBcAb(+), HBsAb(-) negative= resolved infx, occult infx, chronic hepatitis
https://t.co/91ZwqWkdvo https://t.co/c23nN8ER1Y
Dr. John Cush RheumNow ( View Tweet)
#RA pattern of synovitis is well knownn & decr in grip strength seen in Early (39%) & later RA (59% @5y). MCP1 synovitis impacts grip strength most (60%) followed by MCP4 (much less w/ tender/swelling of PIPs,other MCPs). Based on study of 215 early RA pts https://t.co/rTFBHKlNGV https://t.co/zCVsTNuYWW
Dr. John Cush RheumNow ( View Tweet)
ARCTIC Rewind: Three-Year Data in RA
https://t.co/ls2e3LtlvK https://t.co/FtgSq713rc
Dr. John Cush RheumNow ( View Tweet)
Rheum Fellowship Slots Fill Up for 2024
The NRMP announced yesterday that the 2024 rheumatology fellowship match filled 97.6% (124/127) of programs, and 98.9% (273/276) of rheumatology fellowship positions.
https://t.co/wTwajHyal0 https://t.co/JpgDUmioQh
Dr. John Cush RheumNow ( View Tweet)
Early bird pricing has been extended! Register today!
https://t.co/wuvDqE0Qe6 https://t.co/8XXcQUBK6G https://t.co/ISRYMVdRfr
Dr. John Cush RheumNow ( View Tweet)
What do you think of the concept of "dysuricemia" - the concept that both hyperuricemia and hypouricemia influence diseases. “The lower, the better” is incorrect; the ideal is to maintain normouricemia, or optimal SU level, to reduce the urate burden https://t.co/vYSNzWuPVW https://t.co/tde3Mh6Wij
Links:
Dr. John Cush RheumNow ( View Tweet)
Do We Stop or Continue Treatment?
Remission had been a dream, an elusive concept. But then, with the introduction of biologics, conventional synthetic and targeted synthetic DMARDS, patients are able to live longer and with a better quality of life.
https://t.co/2ecihSwGIV https://t.co/rAjHvlyMB8
Dr. John Cush RheumNow ( View Tweet)
WATCH: TMP SMX Prophylaxis in GPA
https://t.co/VEkGFUewjG https://t.co/HouepsLEuw https://t.co/r1kiXejFQn
Dr. John Cush RheumNow ( View Tweet)
The SMART Study: Split Dose Oral Methotrexate
Dr. Jack Cush discusses abstract 1583 presented at the 2023 ACR Convergence meeting in San Diego.
https://t.co/STybvwt9N5 https://t.co/BTwstJiFHr https://t.co/vfb2A5zZAp
Dr. John Cush RheumNow ( View Tweet)
Biologics as First-line Therapy for PMR and GCA?
Dr. Eric Dein talks with Dr. Philip Seo, one of two panelists for the Great Debate: Should PMR and GCA Be Treated with Advanced Therapies at Disease Onset?
https://t.co/eezZkBr8x7 https://t.co/D0dTSkjsNS https://t.co/nBlFyKNkHM
Dr. John Cush RheumNow ( View Tweet)
Can Rheumatologists Accurately Diagnose axSpA in Patients w/Chronic Back Pain?
Chronic low back pain is a common complaint that patients bring to the doctor’s attention.
https://t.co/dnlRtjsUHl https://t.co/wQq1J4Iudf https://t.co/24dQSWlwdr
Links:
Dr. John Cush RheumNow ( View Tweet)
"Protein kinases: drug targets for immunological disorders". Great full-read review from J Shea et al. Reviews Hx, biology, clinical use and safetey of Kinase targeted therapy. https://t.co/T4qMZG2DLI https://t.co/xANcLeiGr6 https://t.co/wAknXuvjl4
Dr. John Cush RheumNow ( View Tweet)